

IAPM PERSONALISED ONCOLOGY IMPLEMENTATION MEETING

PERSONALISED ONCOLOGY ACROSS HEALTH SYSTEMS

Claudia's Journey: From Diagnosis to Measurable Access

FRIDAY
23 OCTOBER 2026

TIME
08:30–17:00

MADRID, SPAIN
Held alongside ESMO
Congress 2026 | Venue

Location: Room « A4.2 » at Mezzanine Level, IFEMA

Meeting purpose: Follow Claudia's pathway from diagnosis and molecular characterisation to eligibility, access, treatment and monitoring, using different cancers and health systems to identify practical guarantees and responsibilities.

Expected outputs: Patient-pathway guarantees • Public–Private Implementation Compact • Innovation & Access Fund recommendation • IAPM Implementation Agenda

PROGRAMME:

08:30 **OPENING**
08:50 “You Have Cancer.” What Happens Next?

Three perspectives on the first effective treatment decision and what patients should expect at 24 hours, 7 days and 1 month.

- **Núria Malats, MD, PhD**, Group Leader, Genetic & Molecular Epidemiology, CNIO, Spain *(confirmed)*
- **Jose Martin Moreno**, Professor of Medicine and Public Health at the University of Valencia *(confirmed)*
- **Denis Horgan, PhD**, Secretary General, IAPM *(confirmed)*

08:50 **SESSION 1**
10:20 Find It. Diagnose It. Characterise It

Early detection, pathology, NGS and liquid biopsy, and clinical utility, with health-system perspectives from Japan, Brazil and Türkiye.

Discussants:

- **Early detection:** **Núria Malats**, Group Leader, Genetic & Molecular Epidemiology, CNIO, Spain *(confirmed)*
- **The Role of AI:** **Arnaud Bayle**, Assistant Professor, Gustave Roussy
- **Longitudinal testing:** **Klaus Pantel**, Chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf
- **Precision oncology / liquid biopsy:** **Helmy Eltoukhy, PhD**, Co-Founder, Chairman and Co-CEO, Guardant Health
- **State of Uptake:** **Nicola Normanno**, Director, IQN-Path *(confirmed)*

- **Health-system perspective:** **Fábio Franke, MD**
- **Patient perspective:** **Ingrid Kruecken**, Vice President, Europa Donna Luxembourg
- **Asia Perspective:** **Janice Tsang**, Specialist in Medical Oncology, Hon. Clinical Assistant Professor, Li Ka Shing Faculty of Medicine, The University of Hong Kong

10:20–10:35: Coffee break

10:35
12:00

SESSION 2 Who Builds the Pathway?

Public–private responsibilities for digital pathology, liquid biopsy, MRD and national networks, with focus on ownership, evidence, financing and implementation.

- **Setting the Scene:** **Vivek Subbiah**, Associate Director, Drug Development & Precision Oncology, Stanford Cancer Institute

Discussants:

- **Digital pathology** **Paul Hofman**, Université Côte d'Azur and Nice University Hospital (*confirmed*)
- **Innovator:** **Jodi Bass**, Vice President, Global Commercial Precision Medicine, Johnson & Johnson Innovative Medicine
- **Lung:** **Ernest Nadal**, Head, Thoracic Tumors Section, Catalan Institute of Oncology
- **Clinical utility** **John W. Longshore, PhD, FACMG**, Head, Scientific Affairs, Global Oncology Diagnostics, AstraZeneca
- **GI Cancers:** **Naureen Starling**, Consultant Medical Oncologist at The Royal Marsden NH
- **Patient:** **Marzia Zambon**, Executive Director, European Donna

12:00: 13:30: Break

13:30
15:00

SESSION 3 The Result Is Back. Can Claudia Actually Receive the Treatment?

Seven cancer pathways test whether molecular eligibility becomes timely treatment or trial access, followed by a cross-cutting discussion on a possible Innovation & Access Fund.

- **Setting the scene:** **José M. Martín-Moreno, MD, PhD**, Professor of Medicine and Public Health, University of Valencia, Spain

Discussants:

Anchor cancer pathways

- **Pancreatic cancer:** **Alfredo Carrato • Núria Malats • Ali Stunt**, Pancreatic Cancer Europe / IRYCIS • CNIO • Pancreatic Cancer Action
- **Innovator perspective:** **Lee-Anne Zinetti**, Executive Director, Global Oncology Portfolio Precision Medicine, Novartis
- **EU Perspective:** **Albrecht Stenzinger**, Institute of Pathology, University Hospital Heidelberg, Germany

Additional cancer lenses

- **Breast cancer:** **Tanja Spanic**, President, Europa Donna Slovenia
- **Lung cancer:** **Óscar Arrieta Rodríguez, MD, MSc**, Instituto Nacional de Cancerología, Mexico

- **Sarcoma:** **Paolo G. Casali, MD**, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan; EURACAN
- **Glioblastoma:** **Wenbin, Li, MD, PhD**, Beijing Tiantan Hospital, Capital Medical University, China

Cross-cutting discussion: Does personalised oncology need an Innovation & Access Fund?

Discussion focus: diagnostics, delivery capacity, evidence-generating access and time-limited transition support between scientific validation, regulatory approval, diagnostic readiness, HTA/reimbursement and routine access.

- **Precision medicine / NGS strategy**
- **Javier Cortés**, International Breast Cancer Center (IBCC), Quironsalud Group, Barcelona, Spain
- **Mark Schmid**, Associate Vice President, Precision Medicine, New Assets (Pipeline) and NGS Strategy, MSD

15:00–15:15: Coffee break

15:15
16:45

SESSION 4

Research Has to Reach Claudia: From European Projects to a Working Patient Pathway

Five European initiatives are tested against a single implementation question: what changes for patients, and what must happen next for that change to reach routine care?

Discussants:

- **David Suñol Moreno**, Advanced Researcher & GenAI Technical Lead, Eurecat - Technology Centre of Catalonia (**iBeChange**)
- **Ralf Hoffmann**, Principal Scientist, Philips; Industry Project Leader, **BRECISE** (confirmed)
- **Leonor Cerdá-Alberich**, Project Coordinator, **SYNTHIA**; IIS La Fe, Spain
- **Manuel Ottaviano**, Project Coordinator, **SPARC**; Universidad Politécnica de Madrid, Spain
- **Elisa Marconi**, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Italy (**ON-COME**)

International implementation response

- **Wadha Al-Muftah**, MENA
- **Wenbin Li**, China
- **Invited respondent (TBC)**, Taiwan

16:45
17:00

CLOSING

The IAPM Personalised Oncology Implementation Agenda

Patient reflection, clinical innovation, health-system implementation and next steps.

- **Clinical + innovation:** **Vivek Subbiah**, Associate Director, Drug Development & Precision Oncology, Stanford Cancer Institute
- **IAPM next steps:** **Denis Horgan**, Secretary General, IAPM

Closing commitment: Publish the Implementation Compact, define the patient-pathway guarantees and convert the day's decisions into the IAPM Personalised Oncology Implementation Agenda.

Programme and faculty are proposed and subject to final confirmation.